The Safety and Effectiveness of Indinavir Plus Ritonavir Plus Two NRTIs in HIV-Infected Patients Who Need Early Intervention Treatment
- Conditions
- HIV Infections
- Registration Number
- NCT00005118
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
The purpose of this study is to see if it is safe and effective to give indinavir plus ritonavir plus 2 NRTIs to HIV-infected patients who need early intervention treatment.
- Detailed Description
Patients receive indinavir bid plus ritonavir bid, plus 2 NRTIs bid (2 new NRTIs or 1 new NRTI and 1 NRTI without evidence of resistance). CD4 cell counts and plasma viral RNA are measured every 4 weeks for the duration of the study. Physical examination and laboratory tests of blood and urine are performed every 4 weeks for the duration of the study. Chest x-ray and 12-lead ECG are done prestudy.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 100
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (40)
Pacific Oaks Research
🇺🇸Beverly Hills, California, United States
Ocean View Internal Medicine
🇺🇸Long Beach, California, United States
Bisher Akil
🇺🇸Los Angeles, California, United States
Tower Infectious Diseases / Med Associates Inc
🇺🇸Los Angeles, California, United States
UCSD Med Ctr - Owen Clinic
🇺🇸San Diego, California, United States
HIV Institute / Davies Med Ctr
🇺🇸San Francisco, California, United States
San Francisco Veterans Adm Med Cntr
🇺🇸San Francisco, California, United States
Avalar Medical Group
🇺🇸Tarzana, California, United States
Harbor - UCLA Med Ctr
🇺🇸Torrance, California, United States
Benjamin Young
🇺🇸Denver, Colorado, United States
Scroll for more (30 remaining)Pacific Oaks Research🇺🇸Beverly Hills, California, United States